Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Sponsored Content by Cerba ResearchMar 16 2023Reviewed by Louis Castel In this interview, Cerba Research explains how its teams were able to assess clinical response in multiple myeloma (MM) patients that were receiving monoclonal antibodies treatment. Could you briefly provide…
In a recent study published in the Proceedings of the National Academy of Sciences, researchers assessed the impact of an anti-CD3 monoclonal antibody (mAb) called Foralumab in coronavirus disease 2019 (COVID-19) treatment. Study: Nasal administration of anti-CD3 mAb (Foralumab) downregulates…
*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information. In a recent study posted to the medRxiv* preprint server, researchers examined…
Three years into the COVID-19 pandemic, new variant outbreaks continue to fuel economic disruptions and hospitalizations across the globe. Effective therapies remain unavailable in much of the world, and circulating variants have rendered monoclonal antibody treatments ineffective. But a new…
*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information. In a recent study posted to the bioRxiv* server, researchers used a…
In a recent study published in Science Immunology, researchers investigated the CAMCI (combination of cell activation and metabolic checkpoint inhibition) strategy as an immunotherapeutic option for inflammatory bowel disease (IDB). Study: CD4+ T cell activation and concomitant mTOR metabolic inhibition…
Scientists have identified an immunogenic epitope at the furin cleavage site of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that induces robust antibody responses in coronavirus disease 2019 (COVID-19) patients. In their study published in the journal eBioMedicine, the researchers…
In a recent study posted to the medRxiv* preprint server, researchers assessed the impact of bebtelovimab (BEB) monoclonal antibody (MAb) in the treatment of high-risk severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-infected patients. Study: Lack of effectiveness of…
Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab-;a novel, patient-tailored monoclonal antibody therapy-;showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers…
In a recent study published in Frontiers in Immunology, a team of researchers from the United States developed an affordable, non-invasive, inhalable prophylactic treatment consisting of immunoglobulin (Ig) A fused nanobodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron…
